SLC5A2 and chronic kidney disease: First, while the CREDENCE and DAPA-CKD trials recruited participants with a UACR exceeding 300 to 5000 mg/g and 200 to 5000 mg/g,46,47 respectively, it has also been reported that fewer than 10% of patients receiving SGLT2 inhibitors present with UACR levels greater than 300 mg/g in kidney care clinics in British Columbia.56 By way of contrast, our study specifically included patients with milder proteinuria levels (eg, UACR >30 mg/g) in order to evaluate the outcomes of SGLT2 inhibitors in a wider T2D with CKD population.